8-K
filed May 7, 2026, 7:59 PM ET
ticker SHPH
CIK 0001757499
M&A
confidence high
sentiment neutral
materiality 0.95
Shuttle Pharmaceuticals Holdings, Inc. (SHPH): M&A transaction — Shuttle Pharma completes merger with United Dogecoin, pivots to crypto, raises $9.55M PIPE
Shuttle Pharmaceuticals Holdings, Inc.
- Merger with United Dogecoin closed May 6; Shuttle issued 8,403 Series B-1 Preferred shares convertible at $1.24.
- Closed $9.55M PIPE financing with Series B-2 Preferred and Common Warrants, convertible at $1.03.
- Appointed Ryan Trasolini (ex-United Dogecoin CEO) as Co-Chief Executive Officer effective at closing.
- Amended Asset Purchase Agreement: paid $3.65M cash, issued 270 Series B-1 shares; seller returned 320,496 common shares.
- Director Oleh Nabyt resigned May 3 with no disagreement with management or board.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ryan Trasolini was appointed as Co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..
- Action
- appointed
- Role
- Co-Chief Executive Officer
Exact text from the filing
the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Oleh Nabyt resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On May 3, 2026 (the “ Termination Date ”), independent director Oleh Nabyt resigned from the Board of Directors of Shuttle, effective as of the Termination Date.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Shuttle Pharmaceuticals Holdings, Inc. completed an acquisition involving United Dogecoin Inc. (closed 2026-05-06).
- Action
- acquisition
- Counterparty
- United Dogecoin Inc.
- Closing
- 2026-05-06
Exact text from the filing
On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Shuttle Pharmaceuticals Holdings, Inc. entered into Agreement and Plan of Merger with United Dogecoin Inc. valued at Agreement and Plan of Merger entered into on April 30, 2026 by and among Acquiror, Merger Sub and th (effective 2026-04-30).
- Action
- entry
- Agreement
- merger
- Counterparty
- United Dogecoin Inc.
- Value
- Agreement and Plan of Merger entered into on April 30, 2026 by and among Acquiror, Merger Sub and th
- Effective
- 2026-04-30
Exact text from the filing
On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Shuttle Pharmaceuticals Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Securities Purchase Agreement for issuance of Series B-2 convertible preferred stock and common stoc (effective 2026-04-30).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- Securities Purchase Agreement for issuance of Series B-2 convertible preferred stock and common stoc
- Effective
- 2026-04-30
Exact text from the filing
on April 30, 2026, the Acquiror entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors party thereto (each, a “ Purchaser ” and collectively, the “ Purchasers ”), pursuant to which the Acquiror agreed to issue (i) 1,910 newly designated Series B-2 convertible preferred stock, par value $0.00001 (the “ Series B-2 Preferred Stock ”) and (ii) common stock purchase warrants (the “ Common Warrants ” and together with the Series B-2 Preferred Stock, the “ PIPE Securities ”) to purchase up to 100% of the number of shares of Common Stock underlying the Series B-2 Convertible Preferred Stock as of the Closing Date, exercisable for a period of three (3) years at an exercise price of $1.03 per share (the “ PIPE Financing ”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.